Azenosertib (ZN-c3) (oral inhibitor of WEE1)

TETON or ZN-c3-004 study. 8/2/21- Ph2 initiated. 11/9/22- Ph2 mono data. 6/18/24- FDA placed partial clinical hold. 9/16/24 Lifts clinical hold.Topline data in H2 '25. 11/10/25:- TETON completed enrollment; further development in USC will be limited to partnering or future capital allocation, and Phase 2 results are planned for publication in H1 2026. 03/26/26:- PR No update. 05/12/26:- PR No update.